The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

The FDA has approved the drug for use in women and girls over the age of 12 who suffer from uncomplicated urinary tract ...

The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract infections (uUTIs) in women and young girls, in a first approval of its ...

Gepotidacin has an entirely new mechanism of action, inhibiting DNA replication via two different type II topoisomerase enzymes, which should make it harder for pathogens to develop resistance.

Moxifloxacin inhibits topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. ≥18yrs: 400mg once daily.

Levofloxacin 5mg/mL; soln for slow IV infusion; preservative-free. Levofloxacin inhibits bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for ...